STANDARD VERSUS BIOFILM SUSCEPTIBILITY TESTING IN CYSTIC FIBROSIS

囊性纤维化的标准与生物膜敏感性测试

• 批准号: 7603356
• 负责人: DANIEL B ROSENBLUTH
• 金额: $ 0.14万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603356
• 关键词: Algorithms; Antibiotic Therapy; Antibiotics; Computer Retrieval of Information on Scientific Projects Database; Cystic Fibrosis; Eligibility Determination; Funding; Grant; Infection; Institution; Microbial Biofilms; Multi-Institutional Clinical Trial; Patients; Predisposition; Protocols documentation; Pseudomonas aeruginosa; Randomized; Research; Research Personnel; Resources; Safety; Source; Sputum; Standards of Weights and Measures; Telephone; Test Result; Testing; United States National Institutes of Health; Upper arm; Visit; clinical efficacy; cystic fibrosis patients; day; follow-up

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a randomized multi-center clinical trial that will compare the microbiological efficacy, clinical effecacy, and safety of using standard versus biofilm susceptibility testing of P. aeruginosa sputum isolates to guide selection form treatment of airway infection in clinically stable patients with CF. Patients will be screened to determine eligibility and to obtain a sputum culture. Eligible patients will be randomized to either the standard or biofilm study arm. Antibiotic selection will be performed centrally according to a standard algorithm using the susceptibility test results of the assigned study arm. On Day 0, patients will be started on a 14-day course of two antibiotics as selected per protocol. Antibiotics will be administered intravenoudly (IV) and / or orally. A follow-up phone call or visit will occur on Day 7. An end of treatment visit will be conducted after completion of antibiotic therapy.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 这是一项随机多中心临床试验，将比较使用铜绿假单胞菌痰分离株的标准药敏试验与生物膜药敏试验的微生物学功效、临床疗效和安全性，以指导临床稳定的 CF 患者选择气道感染治疗方法。 将对患者进行筛查以确定资格并获得痰培养。 符合条件的患者将被随机分配到标准组或生物膜研究组。 将使用指定研究组的药敏测试结果根据标准算法集中进行抗生素选择。 在第 0 天，患者将开始接受根据方案选择的两种抗生素的 14 天疗程。 抗生素将通过静脉内 (IV) 和/或口服给药。 第 7 天将进行后续电话或访视。抗生素治疗完成后将进行治疗结束访视。